Sickle Cell Anemia Disease is an autosomal recessive heredity disorder and it is a growing global health concern. It mainly affects people of African & African American descent, but it does affect people from the Mediterranean, the Middle East, the Caribbean, and Central and South America. Sickle cell anemia transforms healthy red blood cells into deformed sickle cells that restrict or completely obstruct the blood vessel causing weakness, susceptibility to infection, stroke, acute chest syndrome, and death. The highest mortality rates are in young children and infants. There are pain-suppression treatments for sickle cell anemia with the most prominent treatment being a bone marrow transplant from a matched donor, but there is yet to be a permanent cure. Mitigating drugs for sickle cell anemia include hydroxyurea and penicillin prophylaxis, but the drugs are not in commercial use and can sometimes not work due to mutagenicity of the disease. There are various levels of prevention such as genetic counseling and education, and newborn diagnostic screening. Due to various factors such as age, heredity, vitamin D levels, and even air pollution the clinical care knowledge and resources to handle sickle cell admissions is severely deficient. This makes sickle cell anemia remains one of the most misunderstood, silent killers on the planet.